Canada Reports 2nd Blood Clot Case After AstraZeneca Covishield Vaccine

MOSCOW (Sputnik) – A second case of rare blood clots has been found in a patient in Canada who received Covishield, an AstraZeneca vaccine manufactured in India, the Canadian government‘s Health Department said on Sunday.

According to the following statements, the patient diagnosed with blood clots has received treatment and is recovering. Health Canada added that reports of blood clots with low platelets in people vaccinated with the AstraZeneca vaccine remain rare.

The government department also added that “the report of this case shows that Canada’s vaccine safety monitoring system works”.

A health official draws a dose of AstraZeneca’s COVID-19 vaccine manufactured by the Serum Institute of India

Health Canada further reassured citizens that as the COVID-19 vaccine rollout continues in the country, both Health Canada and the Public Health Agency of Canada will continue to monitor the use of all COVID-19 vaccines closely and examine and assess future safety concerns.

Apart from AstraZeneca and Covishield, vaccines developed by Pfizer, Moderna, and Johnson & Johnson have been approved for use in Canada. The total number of people who received at least the first dose of the vaccine has exceeded 7 million.

Sourse: sputniknews.com